Low-dose XXXX maintenance for renal transplant recipients.

@entity1 @entity1011 @entity6 @entity229 @entity205 @entity134 @entity412 @entity618 @entity1140 @entity230 @entity20771 @entity165
OBJECTIVES: We investigated the efficacy and safety of an immunosuppressive regimen consisting of @entity1140 or @entity205 , with basiliximab, @entity618 or @entity20771 , and low-dose @entity230 ( @entity229 <2.5 mg/d) for kidney transplant recipients. METHODS: We conducted a prospective study of 51 recipients with stable graft function who underwent kidney transplantation between August 2005 and December 2009. The oral dose of @entity229 was gradually tapered to <2.5 mg/d within 2 months after transplantation. We assessed, @entity1 and graft survivals, incidence of rejection episodes, transplant function and @entity134 side effects. RESULTS: Death-censored graft survival was 100%, and the mean serum @entity1011 levels remained stable at 1.31, 1.37, and 1.48 mg/dL at 1, 2, and 3 years, respectively, after transplantation. There were seven biopsy-proven rejection episodes (mean = 110 days; range = 14-436) after @entity229 was decreased. The cumulative incidence of biopsy-proven rejection was 11.2%, 17.0%, and 17.0%, respectively. In addition, the mean blood pressure was stable (127/78 mm Hg, 125/77 mm Hg, and 125/76 mmHg, respectively), whereas the mean serum @entity165 and @entity412 levels remained within normal limits. Only 3 @entity1 (7%) displayed new onset @entity6 after transplantation. CONCLUSION: Low-dose @entity134 maintenance therapy is safe with beneficial effects on cardiovascular risk factors.
